APC148 / AdjuTec Pharma - LARVOL DELTA

Safety and pharmacokinetics of single ascending doses of APC148, a zinc-chelating MBL-inhibitor, in healthy volunteers (ESCMID Global 2025) - No abstract available

Clinical • PK/PD data

Metallo-beta-lactamase inhibitor APC148: impact of choice of Mueller-Hinton broth brand on results from antimicrobial susceptibility testing (ESCMID Global 2025) - No abstract available

APC148-001: A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: AdjuTec Pharma AS | Recruiting ➔ Completed

Trial completion

APC148-001: A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: AdjuTec Pharma AS | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2024 ➔ Sep 2024

Enrollment open • Trial initiation date

A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults (clinicaltrials.gov) - P1 | N=46 | Not yet recruiting | Sponsor: AdjuTec Pharma AS

New P1 trial